19
Jun
2024

Zhejiang Langhua Pharmaceutical Co., Ltd.

Exhibitor at CPHI & PMEC China 2024 stand W2B02b, Pharma Ingredients
About Us

Langhua Pharma，FDA, WHO, EDQM, ANVISA and NMPA approved manufacturer in China.Producing APIs, intermediates and Delivering CDMO projects. 
Robust GMP
Strong EHS
Experienced filing in the regulated markets.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CN
  • 2015
    On CPHI since
  • 3
    Certificates
  • 500 - 999
    Employees
Company types
CMO/CDMO
Manufacturer/Innovator
Primary activities
API Producer
Custom Manufacturing/Custom Synthesis
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI & PMEC China 2024
  • 19 - 21 June 2024
  • Shanghai New International Expo Center
  • Visit us at stand W2B02b, Pharma Ingredients

Products Featured at CPHI & PMEC China 2024

  • Spironolactone

    Product Spironolactone

    cardiovascular system drugs CEP and USDMF registered
  • Enrofloxacin

    Product Enrofloxacin

    Third generation Quinolones antibacterial products, veterinary use CEP and USDMF registered
  • Levofloxacin Hemihydrate

    Product Levofloxacin Hemihydrate

    Quinolones antibacterial product, anti-infective CEP , USDMF registered
  • Ciprofloxacin Hydrochloride

    Product Ciprofloxacin Hydrochloride

    Wide-range antibacterial
  • Canrenone

    Product Canrenone

    Intermediate grade: Assay: NLT 90%; NLT 97%. 
    API grade